On July 22, 2026, the US Food and Drug Administration (FDA) announced the approval of zidesamtinib (Jideytro™) to treat patients with locally-advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This approval is for patients who have been previously treated with ROS1-targeted tyrosine kinase inhibitors (TKIs). Mutations in the ROS1 gene are responsible for approximately 2% of NSCLCs. And they are more common in younger patients (median age is 50 years), females, and never-smokers. Zidesamtinib is a type of targeted therapy that is given as a daily pill. It is a tyrosine

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience. Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. Visit the LUNGevity Calendar to see upcoming events like this one. In June, we welcomed Duc Huynh, PharmD, BCOP, MD Anderson Cancer Center, to talk about bone-modifying agents. Topics covered in this 20-minute video include: How do bones naturally change

How do clinical trials work? What actually happens when you enroll in one? And how do you find a trial that's right for you? In this episode, small cell lung cancer survivor Wendy Brooks and thoracic oncologist Arthi Sridhar, MD, UT Southwestern Medical Center, join hosts Ann Steagall and Dr. Misty Shields to break down the intricacies of clinical trials—phases, safeguards in place, and what it's like to be a part of one. Listen as Wendy shares her own experience moving through multiple trials after her cancer progressed on standard treatment. Dr. Sridhar walks through what a clinical trial

What are biomarkers, why do they matter, and what should every person living with lung cancer know about getting tested? Dr. Ross Camidge, a world-renowned thoracic oncologist and lung cancer researcher at the University of Colorado, joins Ann Steagall and Dr. Misty Shields to explain the ins and outs of biomarkers. Dr. Camidge helped pioneer biomarker testing as a standard of care, but he also brings the patient perspective as well - he was diagnosed with EGFR-mutant non-small cell lung cancer several years ago. They discuss what biomarkers are, how biomarker testing works, why you might need

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience. Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. In May, we welcomed Aileen Anglin, ACNP-BC, AOCNP, from MD Anderson Cancer Center, to talk about peripheral neuropathy. Peripheral neuropathy refers to the many conditions that involve damage to the nerves outside of the brain and spinal cord. This can lead

The American Association for Cancer Research (AACR) Annual Meeting brought together thousands of cancer researchers, clinicians, advocates, and patients in San Diego from April 17–22. This year's theme—“Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally”—set a powerful tone for a meeting that showcased advances across the lung cancer landscape. One message was loud and clear. Science is accelerating, and we are reimagining how healthcare is delivered. From next-generation targeted therapies to AI-powered diagnostics, AACR 2026 offered a snapshot of both the

How do you make the most of your visits with your healthcare team? In this episode, lung cancer survivor Bill Morris shares his experience with lung cancer and how he approaches his healthcare visits now. Oncology nurse practitioner Rasheda Persinger shares her insights after 20 years of working with patients. Hosts Ann and Dr. Shields discuss with Bill and Rasheda what they wish every patient knew, from writing down questions before an appointment to asking about biomarker testing to why recording your visit can make all the difference. <a href="https:/

HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer. For the second year in a row, select sessions were recorded so those who could not attend are still able to access the valuable information shared. HOPE Summit 2026 Recorded Sessions Keynote: Wagons Roll with Dr. Ross Camidge Back in the Saddle: Reclaiming Strength and Living Well Charting New Territory with Palliative Care Partners Community Connections Across the Horizon Experts Around the Campfire

What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from initial scans and biopsies through multiple treatments, and the moment a later biopsy revealed a biomarker that led to a targeted therapy. Hosts Ann Steagall and Misty Shields, MD, PhD, then speak with Anne Chiang, MD, PhD, thoracic oncologist at Yale University, about what patients can expect at their first visit, including how doctors determine the type and stage of cancer, plan treatment, and approach care

On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) with mutations in the HER2 gene. This approval expands the usage of this treatment from August 2025 when it was only approved for patients who have been previously treated with a systemic therapy (such as chemotherapy). Mutations in the HER2 gene (also called the ERBB2 gene) are responsible for approximately 2%-3% of nonsquamous NSCLCs. These mutations activate